How Prescription Drugs Get So Wildly Expensive
From the article:
[...] With all that in mind, here’s the important question: Is Shkreli an industry outlier, or was he just unlucky enough to be found out? “There’s one aspect of this that’s an interesting hypothetical,” says [Rachel] Sachs: Would the public be so outraged if he had bought a drug just before it went to market and initially sold it at an inflated price? It’s not at all uncommon for bigger companies to buy biotech startups and independent labs to push drugs through the final stages of clinical trials. [...]
Read The Full Article
Tags
biotechnology fda health care finance health care reform health law policy medicare-medicaid pharmaceuticals